Hovione Technology Acquires Rights to New Blister-Based Inhaler
Hovione Technology has acquired global rights to a dry powder inhaler for pulmonary drug delivery, the Papillon DPI invented by Dr. Klaus-Dieter Beller.
Hovione Technology, a HovioneVentures company, announced in an April 15, 2019 press release that it has secured global rights to develop and commercialize a new, affordable, multi-use blister-based dry powder inhaler (DPI) patented by inventor Dr. Klaus-Dieter Beller. The two parties will continue to collaborate on the inhaler, which will be marketed as the Papillon DPI.
The new device is a single-part, blister-based, reusable inhaler, suitable for both chronic and acute treatments. It can accommodate a single- or double-blister configuration. The unit dose costs are competitive to multi-dose inhalers at a fraction of the development cost and risk associated with complex devices, according to the press release.
Hovione Technology has a co-promotional agreement with API manufacturer Hovione, and together they are able to provide access to a complete portfolio of innovative DPI devices integrated with inhalation API, formulation development, and industrial manufacturing to pharmaceutical companies focusing on inhaled drugs.
Source: Hovione Technology
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
